This is a patient-friendly summary of a research study. The original article can be found here.
There are two main types of stroke:
-
Ischemic stroke happens when a blood clot blocks blood flow in the brain.
-
Hemorrhagic stroke happens when there is bleeding in the brain.
A cavernous malformation (CCM) bleed is a type of hemorrhagic stroke.
When someone has an ischemic stroke, doctors often use a medication called intravenous thrombolysis (IVT) — sometimes called a “clot-busting drug” — to restore blood flow quickly.
However, people who have cerebral cavernous malformations (CCMs) are often considered “higher risk” for this treatment because of concerns that the medication could cause bleeding.
Current Study
Researchers reviewed all published cases of stroke patients with CCM who received clot-busting medication. They analyzed a large U.S. hospital database including 846 stroke patients with CCMs (2016–2022) comparing outcomes between patients who received clot-busting treatment and those who did not.
What They Found
Better early recovery
Patients with CCMs who received clot-busting medication were more likely to go home independently at discharge.
-
About 46% of treated patients went home independently.
-
About 25% of untreated patients did.
No increase in death
The risk of in-hospital death was similar between groups.
No significant increase in bleeding
Importantly, the study did not find a higher rate of dangerous brain bleeding in patients with CCMs who received clot-busting medication compared to those who did not.
What This Means
Historically, clot-busting medication has been considered relatively risky in people with vascular malformations, including CCMs.
In this large national study, clot-busting treatment for ischemic stroke was associated with better early recovery in patients with CCM and did not show an increased risk of bleeding or death. CCM alone should not automatically rule out IVT treatment.
Bottom Line
This large national study provides reassuring evidence that clot-busting treatment may be safe and helpful for some stroke patients with CCM, but medical decisions should always be made on an individual basis.
